Mesoblast Limited
Level 38, 55 Collins Street
Melbourne, VIC 3000
Australia
March 30, 2023
via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| RE: | Mesoblast Limited |
Registration Statement on Form F-3
Filed: March 24, 2023
Securities Act File No. 333-270814
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, Mesoblast Limited (the “Registrant”) hereby respectfully requests acceleration of its Registration Statement on Form F-3 (File No. 333-270814), filed on March 24, 2023, so that it will become effective at 9:00 a.m. (Eastern time) on April 3, 2023, or as soon as practicable thereafter.
If you have any questions, or require any additional information, please do not hesitate to email Andrew Reilly, the Registrant’s outside counsel, at andrew.reilly@rimonlaw.com.
The Registrant hereby acknowledges that, if the Securities and Exchange Commission (or its staff, acting pursuant to delegated authority) (the “Commission”) declares the filing effective, such action:
| (i) | does not foreclose the Commission from taking any action with respect to the filing; |
| (ii) | does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
| (iii) | may not be asserted by the Registrant as a defence in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
| Very truly yours, | ||
| Mesoblast Limited | ||
| By: | /s/ Andrew Chaponnel | |
| Andrew Chaponnel | ||
| Interim Chief Financial Officer | ||
